Next Article in Journal
Comment on “Medical Students’ Attitudes and Perceptions of Influenza and SARS-CoV-2 Vaccination in Cyprus”
Previous Article in Journal
Genotyping of Whipple’s Disease Presenting as Sclerosing Mesenteritis: A Case Report
 
 
GERMS is published by MDPI from Volume 15 Issue 4 (2025). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with the former publisher Infection Science Forum.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Clinical Challenge of Co-Infection of SARS-CoV-2 with Influenza During the Influenza Circulation Season: Suggestions for Prevention

by
Shabnam Dehghan Tarzjani
1,
Sara Kamalzadeh
2,
Majid Taati Moghadam
3,4 and
Mohammad Taghi Ashoobi
5,*
1
Department of Cellular and Molecular Biology, Islamic Azad University, Tehran 1477893855, Iran
2
Department of Microbiology, Faculty of Science, Agriculture and New Technologies, Shiraz Branch, Islamic Azad University of Shiraz, Shiraz 1477893855, Iran
3
Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran 1449614535, Iran
4
Student Research Committee, Iran University of Medical Sciences, Tehran 1449614535, Iran
5
Razi Hospital, Guilan University of Medical Sciences, Rasht 1414489565, Iran
*
Author to whom correspondence should be addressed.
GERMS 2023, 13(2), 188-191; https://doi.org/10.18683/germs.2023.1384
Submission received: 3 January 2023 / Revised: 26 February 2023 / Accepted: 7 May 2023 / Published: 30 June 2023
The scenario of millions of deaths due to the COVID-19 pandemic since its emergence was horrifying, the bitter truth that a virus suddenly overwhelmed the entire world, and humanity was incapable of dealing with it for a long time. [1,2,3] Over time, when the experience and knowledge of the healthcare system increased, successes were achieved in the field of treating COVID-19; however, the emergence of new variants of SARS-CoV-2 was an excessive burden on healthcare staff. Finally, the efforts of the researchers and the healthcare staff led to the provision of various vaccines. [4,5] Even though vaccines are largely effective, vaccination has remained incomplete in many parts of the world as people’s participation in taking booster doses has decreased due to several reasons. [5] A study performed from 13 September to 18 November 2022 revealed the efficacy of a bivalent mRNA vaccine comprising an ancestral SARS-CoV-2 strain component with a restructured component of the Omicron BA.4/BA.5 sub-lineages (after 2, 3, or 4 monovalent doses) in COVID-19–associated emergency department/urgent care encounters was 56% higher compared with no vaccination, 31% higher compared with monovalent vaccination in those who received the last dose 2–4 months earlier, and 50% higher in comparison with monovalent vaccination in those who received the last dose ≥11 months earlier. Bivalent vaccines provided additional protection compared with previous monovalent vaccination and were shown to inhibit COVID-19 compared with no vaccination after administration of two, three, or four monovalent doses. [6] In addition, the Centers for Disease Control and Prevention (CDC) evaluated that 50-74% of people in the United States were vaccinated against influenza during 2021-2022. Although influenza vaccine effectiveness was 36% for all ages in that period, it varied by age group and was lowest among adults 50-64 years (8%) and highest among children aged between 6 months to 4 years (77%). [7] From 1 January to 31 July 2020, a study was performed on 6921 patients with COVID-19 who had received the influenza vaccine before being diagnosed with COVID-19. The results of this study showed the rates of hospitalization and mortality were lower in these patients by 15-24% and 38%, respectively. [8] It was revealed that patients aged >60 years who received an influenza vaccination had a lower probability of death caused by COVID-19 than unvaccinated patients, and the influenza vaccine had a potential protective effect against COVID-19 mortality in the elderly. Receiving the influenza vaccine before the influenza season can decrease the burden of influenza incidence, provide access to essential medical resources to cope with another wave of COVID-19, and reduce the risk of influenza and COVID-19 co-infection. [9] On the other hand, not only are new variants of the SARS-CoV-2 virus spreading, but simultaneous infection of this virus with seasonal influenza has created a major concern. Overall, studies suggest that co-infection of influenza with COVID-19 can lead to interference in the treatment, diagnosis, prognosis of COVID-19, complications of patients’ conditions, increasing death rate, especially in high-risk individuals such as the elderly and children. [10,11,12,13,14] The CDC estimated that during the 2021-2022 influenza season, there were reports of 9 million influenza cases, 4 million medical visits, 10,000 hospitalizations, and 5,000 deaths; however, these figures surged to 25-51 million influenza cases, 12-25 million medical visits, 280000-630000 hospitalizations, and 18000-56000 deaths between 1 October 2022 and 11 February 2023. [15,16] Most reports of co-infection of influenza and COVID-19 have been observed among patients from Asian countries such as China, which may be due to the high population of these nations. [17,18,19] Injury to respiratory cells infected by certain viruses can facilitate the status of infection with SARS-CoV-2. In the cold months of the year, with the start of the seasonal influenza season, there is a higher chance of a coincidence between influenza and COVID-19. Both SARS-CoV-2 and influenza virus A/B can infect patients by respiratory droplets, close contact, and contaminated surfaces and can lead to a wide range of COVID-19 manifestations, from asymptomatic to mild or severe disease, including loss of taste and smell, flu-like symptoms, pneumonia, and even death. [19,20,21] Hence, clinical symptoms are not helpful for the accurate diagnosis and differentiation of these two viruses, and different molecular and serological techniques are required for the accurate diagnosis of COVID-19 and influenza co-infection. [22,23] In addition, it is considered that SARS-CoV-2 preferably infects AT2 pneumocytes (type II alveolar cells), which are the main site of influenza virus replication; therefore, co-infection can lead to the exacerbated manifestations of COVID-19. [24,25] A systematic review suggested that 0.8% of COVID-19-positive patients suffered from influenza, too, but a retrospective study reported that the co-infection rate of influenza and SARS-CoV-2 was as high as 57.3%, of which 49.8% was caused by influenza A virus. Overall, the rate of coinfection with COVID-19 and influenza has been reported between 0.24 and 49.8%. [19,26] The frequency of co-infection in Asia and America was reported at 4.5% and 0.4%, respectively. The prevalence of COVID-19 co-infection with influenza in women (9.1%) was higher than that in men (5.3%), and clinical manifestations such as fever, cough, and shortness of breath were the most common symptoms. A study showed the death rate of patients suffering the coinfection was 6.9%. [19] Another study indicated that COVID-19-positive and influenza-negative patients had shorter hospitalization periods, lower overall mortality, and lower hospital charges, which supported the idea of administrating the influenza vaccine in patients with COVID-19. [8] The coinfection between COVID-19 and seasonal influenza can put a large population at risk. A study on the role of seasonal influenza in the severity of COVID-19 revealed that the initial infection with the influenza A virus positively affects the entry of the SARS-CoV-2 virus into the cells and the infection of animals. [26]
The co-infection with COVID-19 and influenza is of a great importance as it can cause damage to patients and the healthcare section. Also, if this co-infection affects a large population, the healthcare system will be incapacitated. Therefore, this study provides suggestions on how to prevent and reduce the co-infection of these two diseases:
-
Observing the guidelines of the World Health Organization (WHO), such as wearing a mask (especially in closed and crowded spaces), washing hands, maintaining a distance of at least 3 feet, and avoiding unnecessary meetings, should be prioritized.
-
Vaccines for new strains of influenza and the fourth dose of COVID-19 vaccines should be administered, especially for the high-risk population, such as the elderly, those with underlying conditions, immune-deficient patients, and healthcare staff.
-
The production of new influenza vaccines with new technologies which would be effective against new strains of this virus should be prioritized, and surveillance and control of influenza infections should be applied shortly.
-
People with symptoms of a common cold should immediately visit a doctor and receive supportive treatment and observe quarantine conditions to prevent the spread of the disease.
-
Since the students are attending schools and universities in-person again, the rapid transmission of COVID-19 and influenza has increased. As infection can spread among them easily, people with symptoms of respiratory disease and cold should refrain from attending school or university until full recovery.
-
In this situation, the co-infection with influenza and COVID-19 complicates the treatment of patients; if also a co-infection or a secondary infection with bacteria occurs, treatment will be more complicated. Hence, the use of antibiotics in people with symptoms plays a pivotal role in preventing simultaneous bacterial infections, although doctors should prescribe antibiotics according to guidelines to prevent antibiotic resistance.
Although strict devotion to the protocols recommended by the WHO before vaccination reduced viral respiratory diseases such as influenza, co-infection of influenza and COVID-19 in the cold seasons, and the presence of many social activities may increase since the world has not yet recovered from the COVID-19 pandemic. One of the limitations of this study was the lack of sufficient literature on the co-infection of COVID-19 and influenza, especially about the preventing effect of vaccination against co-infection because this hypothesis is still in its initial stages. Therefore, the suggestions presented in this study can help prevent and reduce the simultaneous occurrence of these two infections.

Author Contributions

All authors read and approved the final version of the manuscript.

Funding

None to declare.

Conflicts of interest

All authors—none to declare.

References

  1. Moghadam, M.T.; Taati, B.; Paydar Ardakani, S.M.; Suzuki, K. Ramadan fasting during the COVID-19 pandemic; observance of health, nutrition and exercise criteria for improving the immune system. Front Nutr. 2021, 7, 570235. [Google Scholar] [CrossRef]
  2. Taati Moghadam, M.; Babakhani, S.; Rajabi, S.; Baravati, F.B.; Raeisi, M.; Dousari, A.S. Does stress and anxiety contribute to COVID-19? Iran J Psychiatry Behav Sci. 2021, 15, e106041. [Google Scholar] [CrossRef]
  3. Shokri, A.; Moradi, G.; Moradpour, F.; et al. Influenza incidence overlapped with COVID-19 or under COVID-19 control measures. Immun Inflamm Dis. 2022, 10, e672. [Google Scholar] [CrossRef]
  4. Shakibnia, P.; Ahmadi, R.H.; Fallah, F.; et al. Iran as the center of challenges in the Middle East for the outbreak of COVID-19 Delta variant. Iran Red Crescent Med J. 2021, 23, e1394. [Google Scholar] [CrossRef]
  5. Aminzadeh, S.; Moghadam, M.T. What are the reasons for refusing the booster doses of COVID-19 vaccines? Recommendations and Solutions. Iran Red Crescent Med J. 2022, 24, e2175. [Google Scholar] [CrossRef]
  6. Tenforde, M.W.; Weber, Z.A.; Natarajan, K.; et al. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated Emergency Department or Urgent Care encounters and hospitalizations among immunocompetent adults—VISION Network, nine states, September-November 2022. MMWR Morb Mortal Wkly Rep. 2023, 71, 1637–1646. [Google Scholar] [CrossRef]
  7. Chung, J.R.; Kim, S.S.; Kondor, R.J.; et al. Interim estimates of 2021-22 seasonal influenza vaccine effectiveness—United States, February 2022. MMWR Morb Mortal Wkly Rep. 2022, 71, 365–370. [Google Scholar] [CrossRef]
  8. Garg, I.; Gangu, K.; Shuja, H.; et al. COVID-19 and influenza coinfection outcomes among hospitalized patients in the United States: A propensity matched analysis of national inpatient sample. Vaccines 2022, 10, 2159. [Google Scholar] [CrossRef] [PubMed]
  9. Stańczak-Mrozek, K.I.; Sobczak, A.; Lipiński, L.; et al. The potential benefits of the influenza vaccination on COVID-19 mortality rate-a retrospective analysis of patients in Poland. Vaccines 2021, 10, 5. [Google Scholar] [CrossRef] [PubMed]
  10. Hashemi, S.A.; Safamanesh, S.; Ghafouri, M.; et al. Co-infection with COVID-19 and influenza A virus in two died patients with acute respiratory syndrome, Bojnurd, Iran. J Med Virol. 2020, 92, 2319–2321. [Google Scholar] [CrossRef]
  11. Mardani, M.; Nasiri, M.J. Influenza and COVID-19 Co-infection. Arch Clin Infect Dis. 2022, 17, e131750. [Google Scholar] [CrossRef]
  12. Miron, V.D.; Bar, G.; Filimon, C.; Craiu, M. From COVID-19 to influenza—Real-life clinical practice in a pediatric hospital. Diagnostics 2022, 12, 1208. [Google Scholar] [CrossRef] [PubMed]
  13. Tang, C.Y.; Boftsi, M.; Staudt, L.; et al. SARS-CoV-2 and influenza co-infection: A cross-sectional study in central Missouri during the 2021-2022 influenza season. Virology 2022, 576, 105–110. [Google Scholar] [CrossRef]
  14. Swets, M.C.; Russell, C.D.; Harrison, E.M.; et al. SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet 2022, 399, 1463–1464. [Google Scholar] [CrossRef]
  15. Centers for Disease Control and Prevention. 2021-2022 Estimated Influenza Burden. 2022. Available online: https://www.cdc.gov/flu/about/burden/2021-2022.htm. 202021-22 (accessed on 26 February 2023).
  16. Centers for Disease Control and Prevention. Influenza (Flu): 2022-2023. Available online: https://www.cdc.gov/flu/season/faq-fluseason-2022-2023.htm (accessed on 26 February 2023).
  17. Fanelli, D.; PiazzaF. Analysis and forecast of COVID-19 spreading in China, Italy and France. Chaos Solitons Fractals 2020, 134, 109761. [Google Scholar] [CrossRef]
  18. Khalil, I.; Barma, P. Sub-continental atmosphere and inherent immune system may have impact on novel corona virus’ 2019 (nCovid-19) prevalence in South East Asia. Mymensingh Med J. 2020, 29, 473–480. [Google Scholar] [PubMed]
  19. Dadashi, M.; Khaleghnejad, S.; Abedi Elkhichi, P.; et al. COVID-19 and influenza co-infection: A systematic review and meta-analysis. Front Med (Lausanne) 2021, 8, 681469. [Google Scholar] [CrossRef]
  20. Olsen, S.J.; Winn, A.K.; Budd, A.P.; et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic-United States, 2020-2021. MMWR Morb Mortal Wkly Rep. 2021, 70, 1013–1019. [Google Scholar] [CrossRef]
  21. Hedberg, P.; Johansson, N.; Ternhag, A.; Abdel-Halim, L.; Hedlund, J.; Nauclér, P. Bacterial co-infections in community-acquired pneumonia caused by SARS-CoV-2, influenza virus and respiratory syncytial virus. BMC Infect Dis. 2022, 22, 108. [Google Scholar] [CrossRef] [PubMed]
  22. Ozaras, R.; Cirpin, R.; Duran, A.; et al. Influenza and COVID-19 coinfection: Report of six cases and review of the literature. J Med Virol. 2020, 92, 2657–2665. [Google Scholar] [CrossRef]
  23. Khorramdelazad, H.; Kazemi, M.H.; Najafi, A.; Keykhaee, M.; Emameh, R.Z.; Falak, R. Immunopathological similarities between COVID-19 and influenza: Investigating the consequences of co-infection. Microb Pathog. 2021, 152, 104554. [Google Scholar] [CrossRef] [PubMed]
  24. van Riel, D.; Munster, V.J.; de Wit, E.; et al. Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am J Pathol. 2007, 171, 1215–1223. [Google Scholar] [CrossRef] [PubMed]
  25. St John, A.L.; Rathore, A.P. Early insights into immune responses during COVID-19. J Immunol. 2020, 205, 555–564. [Google Scholar] [CrossRef] [PubMed]
  26. Bai, L.; Zhao, Y.; Dong, J.; et al. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. Cell Res. 2021, 31, 395–403. [Google Scholar] [CrossRef]

Share and Cite

MDPI and ACS Style

Tarzjani, S.D.; Kamalzadeh, S.; Moghadam, M.T.; Ashoobi, M.T. Clinical Challenge of Co-Infection of SARS-CoV-2 with Influenza During the Influenza Circulation Season: Suggestions for Prevention. GERMS 2023, 13, 188-191. https://doi.org/10.18683/germs.2023.1384

AMA Style

Tarzjani SD, Kamalzadeh S, Moghadam MT, Ashoobi MT. Clinical Challenge of Co-Infection of SARS-CoV-2 with Influenza During the Influenza Circulation Season: Suggestions for Prevention. GERMS. 2023; 13(2):188-191. https://doi.org/10.18683/germs.2023.1384

Chicago/Turabian Style

Tarzjani, Shabnam Dehghan, Sara Kamalzadeh, Majid Taati Moghadam, and Mohammad Taghi Ashoobi. 2023. "Clinical Challenge of Co-Infection of SARS-CoV-2 with Influenza During the Influenza Circulation Season: Suggestions for Prevention" GERMS 13, no. 2: 188-191. https://doi.org/10.18683/germs.2023.1384

APA Style

Tarzjani, S. D., Kamalzadeh, S., Moghadam, M. T., & Ashoobi, M. T. (2023). Clinical Challenge of Co-Infection of SARS-CoV-2 with Influenza During the Influenza Circulation Season: Suggestions for Prevention. GERMS, 13(2), 188-191. https://doi.org/10.18683/germs.2023.1384

Article Metrics

Back to TopTop